Jaypirca (pirtobrutinib) approved for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
January 27, 2023New guidance for industry: M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms
January 31, 2023January 30th, 2023 – The Menarini Group, a leading Italian pharmaceutical and diagnostics company, has announced that the U.S. Food and Drug Administration (FDA) has approved Orserdu for the treatment of postmenopausal women or adult men with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Orserdu is approved under the FDA’s Priority Review and Fast Track designation.
- ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers.
- ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat.
- Orserdu is the first endocrine innovation in more than 20 years, specifically addressing ESR1 mutations, a major unmet need.
Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, headquartered in New York will commercialize Orserdu in the U.S.